Alkahest, Inc. clinical trials
Acquired by Grifols, Dec 15, 2020 · source ↗
The registry lists 12 studies whose lead sponsor is Alkahest, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 13, 2024.
Before and after it joined Grifols
- First submitted before Alkahest, Inc. became part of Grifols
- 10
- First submitted after Alkahest, Inc. became part of Grifols
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Phase
- Phase 2
- 10
Registry sponsor names on this page
- Alkahest, Inc.12 studies
Something wrong with this grouping? Tell us on the Grifols page.
Studies
Recruiting first, then most recently updated. Showing 12 of 12. All Grifols studies →
- A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee ArthroplastyCompletedNCT03981419Phase 2
Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols
- A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)TerminatedNCT05038020Phase 2
Sponsor listed in the registry: Alkahest, Inc. · First submitted after Alkahest, Inc. became part of Grifols
- Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on HemodialysisCompletedNCT04985383Not applicable
Sponsor listed in the registry: Alkahest, Inc. · First submitted after Alkahest, Inc. became part of Grifols
- A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous PemphigoidTerminatedNCT04499235Phase 2
Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols
- A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive ImpairmentCompletedNCT04527328Not applicable
Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols
- A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMDCompletedNCT04331730Phase 2
Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols
- Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic TreatmentCompletedNCT04369430Phase 2
Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols
- A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive ImpairmentCompletedNCT03713957Phase 2
Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols
- A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedNCT03520998Phase 2
Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols
- A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's DiseaseCompletedNCT03765762Phase 2
Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols
- Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular DegenerationCompletedNCT03558074Phase 2
Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols
- Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular DegenerationCompletedNCT03558061Phase 2
Sponsor listed in the registry: Alkahest, Inc. · First submitted before Alkahest, Inc. became part of Grifols